Melatonin and the Metabolic Syndrome (MetSyn)

This study has been completed.
Information provided by (Responsible Party):
Michael Kutner, Emory University Identifier:
First received: December 22, 2009
Last updated: February 11, 2015
Last verified: February 2015

December 22, 2009
February 11, 2015
July 2009
June 2012   (final data collection date for primary outcome measure)
Metabolic Syndrome Components [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01038921 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Melatonin and the Metabolic Syndrome
Melatonin Supplementation and the Metabolic Syndrome: A Phase II Crossover Design Clinical Trial
This trial seeks to compare the effects of melatonin supplementation versus placebo in subjects with the metabolic syndrome.
The primary purpose of this Phase II crossover design trial is to examine the safety and efficacy of 8mg of melatonin taken one hour before bedtime compared to a placebo treatment to improve at least one of the five components associated with the metabolic syndrome.
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Metabolic Syndrome
  • Drug: Melatonin
    8 mg dose of Melatonin
  • Drug: Placebo
  • Experimental: Melatonin
    Melatonin 8mg one hour before bedtime for 10 weeks
    Intervention: Drug: Melatonin
  • Placebo Comparator: Placebo
    Placebo administered 1 hour before bedtime for 10 weeks
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2013
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age 30-79 years.
  2. Diagnosed with metabolic syndrome according to AdenosineTriphosphate-III criteria.
  3. Availability for six months after enrolling in the study.

Exclusion Criteria:

  1. Inability to understand informed consent and to cooperate with study procedures.
  2. Supplemental intake of melatonin.
  3. Current smoking.
  4. Current use of calcium channel blockers.
  5. Current, planned, or recent (12 months) participation in another clinical trial.
  6. Women who are pregnant, breast-feeding, attempting conception, or planning to attempt conception over the next 6 months.
  7. Presence of any of the following diagnosed health conditions:

    • Active malignancy other than nonmelanoma skin cancer (current therapy for this malignancy,diagnosis within five years of enrollment, recurrence within five years of enrollment, or metastasis)
    • Uncontrolled hypothyroidism or hyperthyroidism
    • Recent (< 1 year ago) history of heart attack, bypass surgery, angioplasty, or stroke
    • Heart failure (New York Heart Association functional class 3 or 4)
    • On renal dialysis
    • Immunosuppressive therapy (systemic corticosteroids, azathioprine, methotrexate, cyclophosphamide,
    • etc.) or an immunodeficiency syndrome
    • Narcotic or alcohol dependence
    • Obstructive sleep apnea (OSA) , defined either by previous diagnosis (with or without use of nasal CPAP), or by a score of 0.80 or higher on the MAP (Multivariate Apnea Prediction), a validated screening algorithm with high positive and negative predictive value for identifying OSA.
  8. Shift-workers.
30 Years to 79 Years
Contact information is only displayed when the study is recruiting subjects
United States
IRB00014784, R21 AT 004220-01A2
Michael Kutner, Emory University
Emory University
Not Provided
Principal Investigator: Michael H Kutner, PhD Emory University
Study Director: Abinav Goyal, M.D. Emory University
Emory University
February 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP